Heart Failure

Training an AI model to identify LVSD from single-lead ECG data would allow more reliable, earlier diagnosis.

Results show that the new heart failure drug reduces the hospitalizations and risk of death from cardiovascular events.

Two studies show that high heart failure rates in the Black population are a legacy of discriminatory mortgage policies.

The pause was recommended by an independent data safety monitoring board, according to a company press release.

A study in statin-intolerant patients suggests that bempedoic acid reduces the risk of major cardiovascular events significantly.

Some factors found in previous investigations, such as stroke, were not significant in this study, while treatment interruption and severe tricuspid valve regurgitation were newly identified.

Inpefa (sotagliflozin) added 0.39 quality of life years at an incremental lifetime cost of $29,449 for an incremental cost-effectiveness ratio of $75,510 per quality-of-life year gained, according to the study that was sponsored by the drug's maker, Lexicon Pharmaceuticals.

Positive results from a small study suggest that whey protein could have some benefits for people with heart failure, although it is a preliminary finding. Whey protein has a high concentration of leucine, which may help build muscle.

Study shows that every 5% increment in the cardiovascular disease risk as measured by the 10-year Framingham risk score was related to lower cognitive function.

The new report is believed to be among the first to examine cardiovascular risk in myeloproliferative neoplasms through a genetic lens. Mutations in the CALR gene may restore vascular dysfunction in some patients.